Market revenue in 2023 | USD 421.2 million |
Market revenue in 2030 | USD 799.0 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 85.47% in 2023. Horizon Databook has segmented the Japan hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous product developments pertaining to hereditary testing of cancer and noncancer medical conditions in Japan result in its major revenue share in Asia Pacific market. In November 2019, Myriad Genetics, Inc. received approval from Ministry of Health, Labour and Welfare (MHLW), Japan, for BRACAnalysis Diagnostic System.
The system is expected to assist physicians in determining risk of hereditary breast and ovarian cancers in women. It is a genetic test that determines germline mutations in BRCA1/BRCA2 genes. The approval further validated risk assessment in Japanese breast cancer patients.
Myriad, in partnership with SRL Inc., a subsidiary of Miraca Group, markets BRACAnalysis Diagnostic System in Japan. Apart from product development, Japanese government is undertaking several efforts to reinforce the noninvasive prenatal genetic testing in this region.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Japan hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account